Capricor Therapeutics (CAPR) on Thursday announced a regulatory update regarding its Biologics License Application (BLA) for Deramiocel, the company's investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD).
The update follows a recent Type A meeting with the U.S. Food and Drug Administration (FDA) after the receipt of a Complete Response Letter (CRL) in July 2025.
Key outcomes from the meeting include confirmation that the HOPE-3 trial will fulfill the requirement for the additional study outlined in the CRL, and that the HOPE-3 data can be submitted within the current BLA.
The company also noted that the FDA and Capricor have aligned on the endpoints for the HOPE-3 pivotal trial. Capricor plans to submit the HOPE-3 data, expected in the fourth quarter of this year, to support the BLA resubmission.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.